Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026

In this study we investigated the in vitro time dependence of radiosensitisation, pharmacokinetics and metabolism of NU7026, a novel inhibitor of the DNA repair enzyme DNA-dependent protein kinase (DNA-PK). At a dose of 10 μM, which is nontoxic to cells per se, a minimum NU7026 exposure of 4 h in co...

Descripción completa

Detalles Bibliográficos
Autores principales: Nutley, B P, Smith, N F, Hayes, A, Kelland, L R, Brunton, L, Golding, B T, Smith, G C M, Martin, N M B, Workman, P, Raynaud, F I
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361671/
https://www.ncbi.nlm.nih.gov/pubmed/16249792
http://dx.doi.org/10.1038/sj.bjc.6602823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361671/
https://www.ncbi.nlm.nih.gov/pubmed/16249792
http://dx.doi.org/10.1038/sj.bjc.6602823

Ejemplares similares